Lexaria Welcomes Canada’s Proposed Cannabis Legislation

KELOWNA, BC–(Marketwired – April 18, 2017) – Lexaria Bioscience Corp (LXRP)(CSE:LXX) (the “Company”, “Lexaria”) welcomes the newly proposed Canadian legislation designed to allow for adult legal access to Cannabis (the “Cannabis Act”). In line with the Cannabis Act’s objective to protect public health and public safety, powerful demographic and lifestyle forces are trending away from both the harmful effects related to inhalational dosing (smoking/vaping) and from edibles with high sugar & fat content.

The Cannabis Act provides the opportunity for Canada to craft the safest and most responsible cannabis production and consumption framework in the world, especially with respect to consistent and reliable dosing formats that technology such as Lexaria’s enables in modern edible formats. The Cannabis Act prohibits second hand smoke and second hand vapours from inhaled cannabis use, consistent with existing federal legislation that prohibits second hand cigarette smoke. It is also in everyone’s best interest to support the consumer shift away from the high sugar, high fat, inconsistent and unpredictable effectiveness and onset-times associated with edible product formats endemic in other adult-use cannabis markets.

Lexaria’s patented technology — currently subject to collaborative examination together with Canada’s National Research Council — is strongly supportive of macro trends by embracing edible cannabis formats with zero added sugar, and lower micro-dosage unit sizes. Micro dosing of 10mg and even as little as 5mg of THC is rapidly gaining popularity in other legal cannabis jurisdictions that mandate micro dosing edible formats as a more responsible way of consuming cannabis, without creating issues of second hand smoke or second hand vapour for non-consumers. Micro dosing tends to lead to lower overall levels Continue Reading

Comments are closed.